Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ravi Ved

Sports Medicine Pittsburgh, PA Doctor of Osteopathy

NPI 1073956397 CMS profile 877657

1307 Federal St Ste 2, Pittsburgh, PA 15212

Open in the dashboard

General payments

$1,009

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ravi Ved of Pittsburgh, PA is reported in the CMS Open Payments database as having received $1,009 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142 2
2023 General $25 1
2022 General $125 8
2021 General $223 19
2020 General $209 18
2019 General $284 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ravi Ved
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Ravi Ved were reported at $142. Among 132 Sports Medicine profiles paid that year, the median was $99 and the middle half received between $33 and $256.

Show as a table
Year Ravi Ved Sports Medicine median Middle half National median
2019 $284 $131 $46–$324 $163
2020 $209 $96 $34–$276 $114
2021 $223 $120 $33–$421 $132
2022 $125 $107 $31–$274 $149
2023 $25 $63 $25–$180 $160
2024 $0 $104 $28–$282 $164
2025 $142 $99 $33–$256 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $297 14 payments
  2. Horizon Therapeutics plc $254 29 payments
  3. Bioventus LLC $206 5 payments
  4. Electronic Waveform Lab, Inc. $122 8 payments
  5. Flexion Therapeutics, Inc. $90 4 payments
  6. Relievant Medsystems, Inc. $25 1 payment
  7. SI-BONE, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,009 62 payments
Products named General payments · program years 2019–2025
  1. EUFLEXXA $297 14 payments
  2. PENNSAID $226 25 payments
  3. XCELL $121 1 payment
  4. Zilretta $90 4 payments
  5. Exogen $45 2 payments
  6. Exogen Ultrasound Bone Healing System $40 2 payments
  7. DUEXIS $27 4 payments
  8. Intracept Pain $25 1 payment
  9. Intracept Pain $25 1 payment
  10. Intracept Pain $25 1 payment
  11. Other $60 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

616

Median for Sports Medicine: 144

Drug cost

$5,375

Median for Sports Medicine: $1,027

Branded share of claims

3.2%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 77 $1,825
Diclofenac Sodium Generic 64 $1,067
Gabapentin Generic 60 $654
Methylprednisolone Generic 71 $589
Meloxicam Generic 173 $334
Baclofen Generic 25 $306
Cyclobenzaprine Hcl Generic 27 $271
Prednisone Generic 87 $189
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $92
Amitriptyline Hcl Generic 12 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$65,000

Of which drugs: $10,164

Medicare patients

272

Average age 71

Services billed

3,270

173 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 29%
Depression 25%
Diabetes 24%
Osteoporosis 21%
Chronic kidney disease 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 17 77 $6,839
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 114 2,036 $1,455
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 30 74 $324

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record